nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—IRAK4—prostate cancer	0.159	0.375	CbGaD
Gefitinib—CHEK2—prostate cancer	0.0818	0.193	CbGaD
Gefitinib—ERBB3—prostate cancer	0.0729	0.172	CbGaD
Gefitinib—EGFR—prostate cancer	0.0327	0.0772	CbGaD
Gefitinib—CYP3A5—prostate cancer	0.0276	0.0652	CbGaD
Gefitinib—ORM1—Abiraterone—prostate cancer	0.0264	0.0787	CbGbCtD
Gefitinib—EGFR—Docetaxel—prostate cancer	0.0242	0.0721	CbGbCtD
Gefitinib—CYP2C19—prostate cancer	0.0188	0.0444	CbGaD
Gefitinib—CYP1A1—prostate cancer	0.0187	0.0442	CbGaD
Gefitinib—CYP1A1—Flutamide—prostate cancer	0.0148	0.0443	CbGbCtD
Gefitinib—CYP3A4—prostate cancer	0.0119	0.0282	CbGaD
Gefitinib—ABCG2—Cabazitaxel—prostate cancer	0.0119	0.0355	CbGbCtD
Gefitinib—ABCG2—Estrone—prostate cancer	0.0116	0.0347	CbGbCtD
Gefitinib—ALB—Abiraterone—prostate cancer	0.0111	0.0331	CbGbCtD
Gefitinib—CYP1A1—Estrone—prostate cancer	0.0107	0.032	CbGbCtD
Gefitinib—CYP3A5—Flutamide—prostate cancer	0.00891	0.0266	CbGbCtD
Gefitinib—CYP2C19—Nilutamide—prostate cancer	0.00868	0.0259	CbGbCtD
Gefitinib—CYP2C19—Bicalutamide—prostate cancer	0.00868	0.0259	CbGbCtD
Gefitinib—ALB—Estrone—prostate cancer	0.00802	0.0239	CbGbCtD
Gefitinib—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.00798	0.0238	CbGbCtD
Gefitinib—ABCG2—Conjugated Estrogens—prostate cancer	0.00761	0.0227	CbGbCtD
Gefitinib—CYP2C9—Nilutamide—prostate cancer	0.00721	0.0215	CbGbCtD
Gefitinib—CYP2C9—Bicalutamide—prostate cancer	0.00721	0.0215	CbGbCtD
Gefitinib—CYP2C19—Flutamide—prostate cancer	0.00719	0.0215	CbGbCtD
Gefitinib—ABCG2—Mitoxantrone—prostate cancer	0.00692	0.0206	CbGbCtD
Gefitinib—ABCG2—Estradiol—prostate cancer	0.00668	0.0199	CbGbCtD
Gefitinib—CYP2D6—Bicalutamide—prostate cancer	0.0066	0.0197	CbGbCtD
Gefitinib—CYP3A5—Cabazitaxel—prostate cancer	0.00659	0.0197	CbGbCtD
Gefitinib—ABCB1—Estramustine—prostate cancer	0.00651	0.0194	CbGbCtD
Gefitinib—CYP3A5—Estrone—prostate cancer	0.00644	0.0192	CbGbCtD
Gefitinib—CYP1A1—Estradiol—prostate cancer	0.00617	0.0184	CbGbCtD
Gefitinib—CYP2D6—Abiraterone—prostate cancer	0.00546	0.0163	CbGbCtD
Gefitinib—ALB—Estradiol—prostate cancer	0.0046	0.0137	CbGbCtD
Gefitinib—ABCG2—Etoposide—prostate cancer	0.00436	0.013	CbGbCtD
Gefitinib—CYP2C9—Estrone—prostate cancer	0.00432	0.0129	CbGbCtD
Gefitinib—ABCB1—Cabazitaxel—prostate cancer	0.00429	0.0128	CbGbCtD
Gefitinib—CYP3A4—Bicalutamide—prostate cancer	0.00419	0.0125	CbGbCtD
Gefitinib—ABCB1—Estrone—prostate cancer	0.00419	0.0125	CbGbCtD
Gefitinib—ABCG2—Docetaxel—prostate cancer	0.00399	0.0119	CbGbCtD
Gefitinib—ALB—Prednisone—prostate cancer	0.00396	0.0118	CbGbCtD
Gefitinib—CYP3A4—Estramustine—prostate cancer	0.0039	0.0116	CbGbCtD
Gefitinib—ABCB1—Ethinyl Estradiol—prostate cancer	0.00374	0.0112	CbGbCtD
Gefitinib—CYP3A5—Estradiol—prostate cancer	0.0037	0.011	CbGbCtD
Gefitinib—CYP3A4—Abiraterone—prostate cancer	0.00347	0.0104	CbGbCtD
Gefitinib—CYP3A4—Flutamide—prostate cancer	0.00347	0.0104	CbGbCtD
Gefitinib—CYP2C9—Capecitabine—prostate cancer	0.00327	0.00977	CbGbCtD
Gefitinib—CYP2C19—Estradiol—prostate cancer	0.00298	0.00891	CbGbCtD
Gefitinib—ABCG2—Doxorubicin—prostate cancer	0.00297	0.00888	CbGbCtD
Gefitinib—ABCB1—Conjugated Estrogens—prostate cancer	0.00274	0.00819	CbGbCtD
Gefitinib—CYP3A4—Cabazitaxel—prostate cancer	0.00257	0.00767	CbGbCtD
Gefitinib—CYP2C19—Prednisone—prostate cancer	0.00257	0.00766	CbGbCtD
Gefitinib—CYP3A4—Estrone—prostate cancer	0.00251	0.0075	CbGbCtD
Gefitinib—ABCB1—Mitoxantrone—prostate cancer	0.00249	0.00744	CbGbCtD
Gefitinib—CYP2C9—Estradiol—prostate cancer	0.00248	0.00741	CbGbCtD
Gefitinib—CYP3A5—Etoposide—prostate cancer	0.00242	0.00721	CbGbCtD
Gefitinib—ABCB1—Estradiol—prostate cancer	0.00241	0.00719	CbGbCtD
Gefitinib—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00224	0.00668	CbGbCtD
Gefitinib—CYP3A5—Docetaxel—prostate cancer	0.00221	0.0066	CbGbCtD
Gefitinib—ABCB1—Prednisone—prostate cancer	0.00207	0.00618	CbGbCtD
Gefitinib—CYP3A4—Conjugated Estrogens—prostate cancer	0.00164	0.00491	CbGbCtD
Gefitinib—ABCB1—Etoposide—prostate cancer	0.00157	0.00469	CbGbCtD
Gefitinib—CHEK2—prostate gland—prostate cancer	0.00154	0.0372	CbGeAlD
Gefitinib—CYP3A4—Mitoxantrone—prostate cancer	0.00149	0.00446	CbGbCtD
Gefitinib—CYP3A4—Estradiol—prostate cancer	0.00144	0.00431	CbGbCtD
Gefitinib—ABCB1—Docetaxel—prostate cancer	0.00144	0.00429	CbGbCtD
Gefitinib—EPHA6—prostate gland—prostate cancer	0.00138	0.0334	CbGeAlD
Gefitinib—CYP3A4—Prednisone—prostate cancer	0.00124	0.0037	CbGbCtD
Gefitinib—ABCB1—Doxorubicin—prostate cancer	0.00107	0.0032	CbGbCtD
Gefitinib—CYP2C19—urine—prostate cancer	0.00104	0.0251	CbGeAlD
Gefitinib—EGFR—prostate gland—prostate cancer	0.00101	0.0245	CbGeAlD
Gefitinib—CYP2D6—Doxorubicin—prostate cancer	0.00101	0.00302	CbGbCtD
Gefitinib—CSNK1E—prostate gland—prostate cancer	0.000975	0.0236	CbGeAlD
Gefitinib—IRAK4—prostate gland—prostate cancer	0.00096	0.0232	CbGeAlD
Gefitinib—CYP3A4—Etoposide—prostate cancer	0.000942	0.00281	CbGbCtD
Gefitinib—ERBB3—prostate gland—prostate cancer	0.000941	0.0228	CbGeAlD
Gefitinib—MKNK2—prostate gland—prostate cancer	0.000894	0.0216	CbGeAlD
Gefitinib—IRAK1—prostate gland—prostate cancer	0.000894	0.0216	CbGeAlD
Gefitinib—MKNK1—prostate gland—prostate cancer	0.000883	0.0214	CbGeAlD
Gefitinib—CYP3A4—Docetaxel—prostate cancer	0.000862	0.00257	CbGbCtD
Gefitinib—CSNK1E—seminal vesicle—prostate cancer	0.000824	0.02	CbGeAlD
Gefitinib—IRAK4—seminal vesicle—prostate cancer	0.000812	0.0196	CbGeAlD
Gefitinib—CYP2C9—urine—prostate cancer	0.000804	0.0195	CbGeAlD
Gefitinib—CHEK2—bone marrow—prostate cancer	0.000792	0.0192	CbGeAlD
Gefitinib—SBK1—testis—prostate cancer	0.000777	0.0188	CbGeAlD
Gefitinib—HIPK4—testis—prostate cancer	0.000769	0.0186	CbGeAlD
Gefitinib—MKNK2—seminal vesicle—prostate cancer	0.000756	0.0183	CbGeAlD
Gefitinib—STK10—prostate gland—prostate cancer	0.000727	0.0176	CbGeAlD
Gefitinib—ERBB3—epithelium—prostate cancer	0.000691	0.0167	CbGeAlD
Gefitinib—CHEK2—testis—prostate cancer	0.000677	0.0164	CbGeAlD
Gefitinib—MKNK2—epithelium—prostate cancer	0.000657	0.0159	CbGeAlD
Gefitinib—CSNK1E—urethra—prostate cancer	0.000653	0.0158	CbGeAlD
Gefitinib—MAP2K5—prostate gland—prostate cancer	0.000649	0.0157	CbGeAlD
Gefitinib—CYP3A4—Doxorubicin—prostate cancer	0.000643	0.00192	CbGbCtD
Gefitinib—IRAK4—urethra—prostate cancer	0.000642	0.0156	CbGeAlD
Gefitinib—ERBB3—renal system—prostate cancer	0.000641	0.0155	CbGeAlD
Gefitinib—CYP3A4—urine—prostate cancer	0.000613	0.0148	CbGeAlD
Gefitinib—MKNK2—renal system—prostate cancer	0.00061	0.0148	CbGeAlD
Gefitinib—EPHA6—testis—prostate cancer	0.000607	0.0147	CbGeAlD
Gefitinib—CYP2D6—urine—prostate cancer	0.000603	0.0146	CbGeAlD
Gefitinib—MKNK2—urethra—prostate cancer	0.000599	0.0145	CbGeAlD
Gefitinib—MKNK1—urethra—prostate cancer	0.000591	0.0143	CbGeAlD
Gefitinib—SBK1—lymph node—prostate cancer	0.000564	0.0136	CbGeAlD
Gefitinib—MAP3K19—testis—prostate cancer	0.000552	0.0134	CbGeAlD
Gefitinib—MAP2K5—seminal vesicle—prostate cancer	0.000549	0.0133	CbGeAlD
Gefitinib—ORM1—prostate gland—prostate cancer	0.000527	0.0128	CbGeAlD
Gefitinib—STK10—renal system—prostate cancer	0.000496	0.012	CbGeAlD
Gefitinib—IRAK4—bone marrow—prostate cancer	0.000494	0.012	CbGeAlD
Gefitinib—CHEK2—lymph node—prostate cancer	0.000491	0.0119	CbGeAlD
Gefitinib—MKNK2—bone marrow—prostate cancer	0.000461	0.0112	CbGeAlD
Gefitinib—IRAK1—bone marrow—prostate cancer	0.000461	0.0112	CbGeAlD
Gefitinib—MKNK1—bone marrow—prostate cancer	0.000455	0.011	CbGeAlD
Gefitinib—EGFR—testis—prostate cancer	0.000447	0.0108	CbGeAlD
Gefitinib—CHEK2—Docetaxel—Cabazitaxel—prostate cancer	0.000446	0.18	CbGdCrCtD
Gefitinib—MAP2K5—urethra—prostate cancer	0.000435	0.0105	CbGeAlD
Gefitinib—CSNK1E—testis—prostate cancer	0.000429	0.0104	CbGeAlD
Gefitinib—IRAK4—testis—prostate cancer	0.000423	0.0102	CbGeAlD
Gefitinib—ERBB3—testis—prostate cancer	0.000414	0.01	CbGeAlD
Gefitinib—MKNK2—testis—prostate cancer	0.000394	0.00954	CbGeAlD
Gefitinib—IRAK1—testis—prostate cancer	0.000394	0.00954	CbGeAlD
Gefitinib—MKNK1—testis—prostate cancer	0.000389	0.00942	CbGeAlD
Gefitinib—STK10—bone marrow—prostate cancer	0.000375	0.00907	CbGeAlD
Gefitinib—Lapatinib—ERBB2—prostate cancer	0.000324	0.0754	CrCbGaD
Gefitinib—EGFR—lymph node—prostate cancer	0.000324	0.00784	CbGeAlD
Gefitinib—STK10—testis—prostate cancer	0.00032	0.00775	CbGeAlD
Gefitinib—ABCG2—prostate gland—prostate cancer	0.000316	0.00765	CbGeAlD
Gefitinib—CSNK1E—lymph node—prostate cancer	0.000311	0.00753	CbGeAlD
Gefitinib—CHEK2—Paclitaxel—Cabazitaxel—prostate cancer	0.000308	0.124	CbGdCrCtD
Gefitinib—IRAK4—lymph node—prostate cancer	0.000306	0.00742	CbGeAlD
Gefitinib—ERBB3—lymph node—prostate cancer	0.0003	0.00727	CbGeAlD
Gefitinib—CYP3A5—prostate gland—prostate cancer	0.000293	0.0071	CbGeAlD
Gefitinib—MAP2K5—testis—prostate cancer	0.000286	0.00693	CbGeAlD
Gefitinib—MKNK2—lymph node—prostate cancer	0.000286	0.00691	CbGeAlD
Gefitinib—IRAK1—lymph node—prostate cancer	0.000286	0.00691	CbGeAlD
Gefitinib—MKNK1—lymph node—prostate cancer	0.000282	0.00683	CbGeAlD
Gefitinib—ORM1—bone marrow—prostate cancer	0.000272	0.00658	CbGeAlD
Gefitinib—ABCG2—seminal vesicle—prostate cancer	0.000267	0.00647	CbGeAlD
Gefitinib—Bosutinib—EPHB2—prostate cancer	0.000257	0.06	CrCbGaD
Gefitinib—Bosutinib—PRKCQ—prostate cancer	0.000257	0.06	CrCbGaD
Gefitinib—Vandetanib—BMPR1B—prostate cancer	0.000245	0.0572	CrCbGaD
Gefitinib—Vandetanib—IRAK4—prostate cancer	0.000245	0.0572	CrCbGaD
Gefitinib—STK10—lymph node—prostate cancer	0.000232	0.00562	CbGeAlD
Gefitinib—Afatinib—ERBB2—prostate cancer	0.00023	0.0535	CrCbGaD
Gefitinib—Bosutinib—IRAK4—prostate cancer	0.00023	0.0535	CrCbGaD
Gefitinib—CYP1A1—epithelium—prostate cancer	0.00022	0.00534	CbGeAlD
Gefitinib—MKNK1—Estradiol—Estradiol valerate/Dienogest—prostate cancer	0.000215	0.0865	CbGdCrCtD
Gefitinib—ABCG2—urethra—prostate cancer	0.000212	0.00512	CbGeAlD
Gefitinib—MAP2K5—lymph node—prostate cancer	0.000207	0.00502	CbGeAlD
Gefitinib—CYP1A1—renal system—prostate cancer	0.000204	0.00495	CbGeAlD
Gefitinib—ALB—testis—prostate cancer	0.000204	0.00493	CbGeAlD
Gefitinib—CYP1A1—urethra—prostate cancer	0.000201	0.00486	CbGeAlD
Gefitinib—CYP3A5—renal system—prostate cancer	0.0002	0.00484	CbGeAlD
Gefitinib—MKNK1—Estradiol—Estramustine—prostate cancer	0.000183	0.0735	CbGdCrCtD
Gefitinib—Bosutinib—MAP3K7—prostate cancer	0.000174	0.0405	CrCbGaD
Gefitinib—ORM1—lymph node—prostate cancer	0.000168	0.00408	CbGeAlD
Gefitinib—ABCG2—bone marrow—prostate cancer	0.000163	0.00394	CbGeAlD
Gefitinib—ABCB1—prostate gland—prostate cancer	0.000156	0.00377	CbGeAlD
Gefitinib—Lapatinib—EGFR—prostate cancer	0.000153	0.0357	CrCbGaD
Gefitinib—CYP3A4—renal system—prostate cancer	0.00015	0.00363	CbGeAlD
Gefitinib—Bosutinib—MAP2K1—prostate cancer	0.000148	0.0344	CrCbGaD
Gefitinib—ALB—lymph node—prostate cancer	0.000148	0.00357	CbGeAlD
Gefitinib—CYP2D6—renal system—prostate cancer	0.000148	0.00357	CbGeAlD
Gefitinib—MKNK1—Estradiol—Estrone—prostate cancer	0.000145	0.0584	CbGdCrCtD
Gefitinib—ABCG2—testis—prostate cancer	0.000139	0.00337	CbGeAlD
Gefitinib—ABCB1—seminal vesicle—prostate cancer	0.000132	0.00319	CbGeAlD
Gefitinib—Lapatinib—CYP3A5—prostate cancer	0.000129	0.0301	CrCbGaD
Gefitinib—CHEK2—Paclitaxel—Docetaxel—prostate cancer	0.000128	0.0515	CbGdCrCtD
Gefitinib—MKNK1—Estradiol—Conjugated Estrogens—prostate cancer	0.000128	0.0514	CbGdCrCtD
Gefitinib—ERBB3—Podofilox—Etoposide—prostate cancer	0.000122	0.049	CbGdCrCtD
Gefitinib—Minaprine—ACHE—prostate cancer	0.000121	0.0281	CrCbGaD
Gefitinib—Bosutinib—CHEK2—prostate cancer	0.000118	0.0275	CrCbGaD
Gefitinib—ABCB1—epithelium—prostate cancer	0.000114	0.00277	CbGeAlD
Gefitinib—Vandetanib—ERBB3—prostate cancer	0.000113	0.0262	CrCbGaD
Gefitinib—Afatinib—EGFR—prostate cancer	0.000109	0.0253	CrCbGaD
Gefitinib—MKNK1—Estradiol—Ethinyl Estradiol—prostate cancer	0.000107	0.0432	CbGdCrCtD
Gefitinib—ABCB1—renal system—prostate cancer	0.000106	0.00257	CbGeAlD
Gefitinib—Bosutinib—ERBB3—prostate cancer	0.000105	0.0245	CrCbGaD
Gefitinib—ABCB1—urethra—prostate cancer	0.000104	0.00252	CbGeAlD
Gefitinib—ABCG2—lymph node—prostate cancer	0.000101	0.00244	CbGeAlD
Gefitinib—CHEK2—Testosterone Propionate—Estradiol valerate/Dienogest—prostate cancer	9.8e-05	0.0395	CbGdCrCtD
Gefitinib—CYP1A1—lymph node—prostate cancer	9.58e-05	0.00232	CbGeAlD
Gefitinib—CYP2D6—testis—prostate cancer	9.54e-05	0.00231	CbGeAlD
Gefitinib—CHEK2—Fulvestrant—Estradiol—prostate cancer	9.33e-05	0.0376	CbGdCrCtD
Gefitinib—Vandetanib—PDGFRB—prostate cancer	9.32e-05	0.0217	CrCbGaD
Gefitinib—Lapatinib—CYP2C19—prostate cancer	8.79e-05	0.0205	CrCbGaD
Gefitinib—Bosutinib—PDGFRB—prostate cancer	8.72e-05	0.0203	CrCbGaD
Gefitinib—CHEK2—Podofilox—Etoposide—prostate cancer	8.21e-05	0.0331	CbGdCrCtD
Gefitinib—CHEK2—Teniposide—Etoposide—prostate cancer	8.21e-05	0.0331	CbGdCrCtD
Gefitinib—Erlotinib—CYP1B1—prostate cancer	8.12e-05	0.0189	CrCbGaD
Gefitinib—ABCB1—bone marrow—prostate cancer	8.03e-05	0.00194	CbGeAlD
Gefitinib—CSNK1E—Danazol—Ethinyl Estradiol—prostate cancer	7.95e-05	0.032	CbGdCrCtD
Gefitinib—Erlotinib—EGFR—prostate cancer	7.67e-05	0.0179	CrCbGaD
Gefitinib—Vandetanib—SRC—prostate cancer	7.52e-05	0.0175	CrCbGaD
Gefitinib—Vandetanib—KDR—prostate cancer	7.06e-05	0.0164	CrCbGaD
Gefitinib—Bosutinib—SRC—prostate cancer	7.03e-05	0.0164	CrCbGaD
Gefitinib—ABCB1—testis—prostate cancer	6.86e-05	0.00166	CbGeAlD
Gefitinib—Erlotinib—CYP3A5—prostate cancer	6.47e-05	0.0151	CrCbGaD
Gefitinib—Cisapride—CYP3A5—prostate cancer	6.09e-05	0.0142	CrCbGaD
Gefitinib—Vandetanib—VEGFA—prostate cancer	5.99e-05	0.0139	CrCbGaD
Gefitinib—Cisapride—CYP2A6—prostate cancer	5.9e-05	0.0137	CrCbGaD
Gefitinib—Iloperidone—CYP3A5—prostate cancer	5.62e-05	0.0131	CrCbGaD
Gefitinib—Lapatinib—CYP3A4—prostate cancer	5.59e-05	0.013	CrCbGaD
Gefitinib—Vandetanib—EGFR—prostate cancer	5.05e-05	0.0118	CrCbGaD
Gefitinib—ABCB1—lymph node—prostate cancer	4.97e-05	0.0012	CbGeAlD
Gefitinib—Bosutinib—EGFR—prostate cancer	4.72e-05	0.011	CrCbGaD
Gefitinib—Erlotinib—CYP1A1—prostate cancer	4.39e-05	0.0102	CrCbGaD
Gefitinib—CHEK2—Doxorubicin—Epirubicin—prostate cancer	4.28e-05	0.0173	CbGdCrCtD
Gefitinib—Alanine aminotransferase increased—Epirubicin—prostate cancer	4.16e-05	0.000427	CcSEcCtD
Gefitinib—Cisapride—CYP2C19—prostate cancer	4.15e-05	0.00966	CrCbGaD
Gefitinib—Alopecia—Capecitabine—prostate cancer	4.13e-05	0.000424	CcSEcCtD
Gefitinib—Infection—Etoposide—prostate cancer	4.1e-05	0.000421	CcSEcCtD
Gefitinib—Malnutrition—Capecitabine—prostate cancer	4.07e-05	0.000418	CcSEcCtD
Gefitinib—CHEK2—Danazol—Ethinyl Estradiol—prostate cancer	4.07e-05	0.0164	CbGdCrCtD
Gefitinib—Gastrointestinal pain—Mitoxantrone—prostate cancer	4.06e-05	0.000417	CcSEcCtD
Gefitinib—Dehydration—Doxorubicin—prostate cancer	4.05e-05	0.000416	CcSEcCtD
Gefitinib—Thrombocytopenia—Etoposide—prostate cancer	4.05e-05	0.000415	CcSEcCtD
Gefitinib—Skin disorder—Etoposide—prostate cancer	4.01e-05	0.000412	CcSEcCtD
Gefitinib—Dry skin—Doxorubicin—prostate cancer	4e-05	0.00041	CcSEcCtD
Gefitinib—Nausea—Goserelin—prostate cancer	3.99e-05	0.00041	CcSEcCtD
Gefitinib—Pancreatitis—Epirubicin—prostate cancer	3.99e-05	0.00041	CcSEcCtD
Gefitinib—Hypokalaemia—Doxorubicin—prostate cancer	3.97e-05	0.000407	CcSEcCtD
Gefitinib—CHEK2—Epirubicin—Doxorubicin—prostate cancer	3.96e-05	0.016	CbGdCrCtD
Gefitinib—Nausea—Conjugated Estrogens—prostate cancer	3.96e-05	0.000406	CcSEcCtD
Gefitinib—Urticaria—Mitoxantrone—prostate cancer	3.95e-05	0.000405	CcSEcCtD
Gefitinib—Anorexia—Etoposide—prostate cancer	3.94e-05	0.000404	CcSEcCtD
Gefitinib—Hypersensitivity—Estradiol—prostate cancer	3.93e-05	0.000403	CcSEcCtD
Gefitinib—Body temperature increased—Mitoxantrone—prostate cancer	3.93e-05	0.000403	CcSEcCtD
Gefitinib—Abdominal pain—Mitoxantrone—prostate cancer	3.93e-05	0.000403	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Doxorubicin—prostate cancer	3.93e-05	0.000403	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Doxorubicin—prostate cancer	3.93e-05	0.000403	CcSEcCtD
Gefitinib—Eye disorder—Prednisone—prostate cancer	3.9e-05	0.0004	CcSEcCtD
Gefitinib—Anaemia—Docetaxel—prostate cancer	3.89e-05	0.000399	CcSEcCtD
Gefitinib—Iloperidone—CYP2E1—prostate cancer	3.87e-05	0.009	CrCbGaD
Gefitinib—Hypotension—Etoposide—prostate cancer	3.86e-05	0.000396	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Doxorubicin—prostate cancer	3.85e-05	0.000395	CcSEcCtD
Gefitinib—Asthenia—Estradiol—prostate cancer	3.82e-05	0.000393	CcSEcCtD
Gefitinib—Angiopathy—Prednisone—prostate cancer	3.78e-05	0.000388	CcSEcCtD
Gefitinib—Pruritus—Estradiol—prostate cancer	3.77e-05	0.000387	CcSEcCtD
Gefitinib—Anaemia—Capecitabine—prostate cancer	3.76e-05	0.000386	CcSEcCtD
Gefitinib—Arrhythmia—Prednisone—prostate cancer	3.72e-05	0.000382	CcSEcCtD
Gefitinib—Pancreatitis—Doxorubicin—prostate cancer	3.69e-05	0.000379	CcSEcCtD
Gefitinib—Weight decreased—Epirubicin—prostate cancer	3.68e-05	0.000378	CcSEcCtD
Gefitinib—Dyspnoea—Etoposide—prostate cancer	3.68e-05	0.000378	CcSEcCtD
Gefitinib—Alopecia—Prednisone—prostate cancer	3.68e-05	0.000378	CcSEcCtD
Gefitinib—Malaise—Capecitabine—prostate cancer	3.67e-05	0.000377	CcSEcCtD
Gefitinib—Cough—Docetaxel—prostate cancer	3.67e-05	0.000377	CcSEcCtD
Gefitinib—CHEK2—Norethindrone—Ethinyl Estradiol—prostate cancer	3.67e-05	0.0148	CbGdCrCtD
Gefitinib—Hypersensitivity—Mitoxantrone—prostate cancer	3.66e-05	0.000376	CcSEcCtD
Gefitinib—Pneumonia—Epirubicin—prostate cancer	3.65e-05	0.000375	CcSEcCtD
Gefitinib—Diarrhoea—Estradiol—prostate cancer	3.65e-05	0.000374	CcSEcCtD
Gefitinib—Infestation NOS—Epirubicin—prostate cancer	3.63e-05	0.000373	CcSEcCtD
Gefitinib—Infestation—Epirubicin—prostate cancer	3.63e-05	0.000373	CcSEcCtD
Gefitinib—Malnutrition—Prednisone—prostate cancer	3.63e-05	0.000372	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Epirubicin—prostate cancer	3.6e-05	0.00037	CcSEcCtD
Gefitinib—Decreased appetite—Etoposide—prostate cancer	3.59e-05	0.000369	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Etoposide—prostate cancer	3.57e-05	0.000366	CcSEcCtD
Gefitinib—Asthenia—Mitoxantrone—prostate cancer	3.56e-05	0.000366	CcSEcCtD
Gefitinib—Fatigue—Etoposide—prostate cancer	3.56e-05	0.000366	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	3.56e-05	0.000365	CcSEcCtD
Gefitinib—Cough—Capecitabine—prostate cancer	3.55e-05	0.000365	CcSEcCtD
Gefitinib—Stomatitis—Epirubicin—prostate cancer	3.54e-05	0.000363	CcSEcCtD
Gefitinib—Pain—Etoposide—prostate cancer	3.53e-05	0.000363	CcSEcCtD
Gefitinib—Constipation—Etoposide—prostate cancer	3.53e-05	0.000363	CcSEcCtD
Gefitinib—Conjunctivitis—Epirubicin—prostate cancer	3.53e-05	0.000362	CcSEcCtD
Gefitinib—Dry mouth—Docetaxel—prostate cancer	3.5e-05	0.00036	CcSEcCtD
Gefitinib—Haematuria—Epirubicin—prostate cancer	3.46e-05	0.000355	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	3.44e-05	0.000354	CcSEcCtD
Gefitinib—Hepatobiliary disease—Epirubicin—prostate cancer	3.43e-05	0.000353	CcSEcCtD
Gefitinib—Epistaxis—Epirubicin—prostate cancer	3.43e-05	0.000352	CcSEcCtD
Gefitinib—Infection—Docetaxel—prostate cancer	3.41e-05	0.00035	CcSEcCtD
Gefitinib—Weight decreased—Doxorubicin—prostate cancer	3.41e-05	0.00035	CcSEcCtD
Gefitinib—Diarrhoea—Mitoxantrone—prostate cancer	3.4e-05	0.000349	CcSEcCtD
Gefitinib—Dry mouth—Capecitabine—prostate cancer	3.39e-05	0.000348	CcSEcCtD
Gefitinib—Vomiting—Estradiol—prostate cancer	3.39e-05	0.000348	CcSEcCtD
Gefitinib—Pneumonia—Doxorubicin—prostate cancer	3.38e-05	0.000347	CcSEcCtD
Gefitinib—Gastrointestinal pain—Etoposide—prostate cancer	3.38e-05	0.000347	CcSEcCtD
Gefitinib—Shock—Docetaxel—prostate cancer	3.38e-05	0.000347	CcSEcCtD
Gefitinib—Nervous system disorder—Docetaxel—prostate cancer	3.37e-05	0.000346	CcSEcCtD
Gefitinib—Thrombocytopenia—Docetaxel—prostate cancer	3.36e-05	0.000345	CcSEcCtD
Gefitinib—Rash—Estradiol—prostate cancer	3.36e-05	0.000345	CcSEcCtD
Gefitinib—Infestation NOS—Doxorubicin—prostate cancer	3.36e-05	0.000345	CcSEcCtD
Gefitinib—Infestation—Doxorubicin—prostate cancer	3.36e-05	0.000345	CcSEcCtD
Gefitinib—Dermatitis—Estradiol—prostate cancer	3.36e-05	0.000345	CcSEcCtD
Gefitinib—Anaemia—Prednisone—prostate cancer	3.35e-05	0.000344	CcSEcCtD
Gefitinib—Skin disorder—Docetaxel—prostate cancer	3.34e-05	0.000342	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	3.33e-05	0.000342	CcSEcCtD
Gefitinib—Angioedema—Prednisone—prostate cancer	3.32e-05	0.00034	CcSEcCtD
Gefitinib—Infection—Capecitabine—prostate cancer	3.3e-05	0.000339	CcSEcCtD
Gefitinib—Urticaria—Etoposide—prostate cancer	3.28e-05	0.000337	CcSEcCtD
Gefitinib—Haemoglobin—Epirubicin—prostate cancer	3.28e-05	0.000336	CcSEcCtD
Gefitinib—Stomatitis—Doxorubicin—prostate cancer	3.28e-05	0.000336	CcSEcCtD
Gefitinib—Anorexia—Docetaxel—prostate cancer	3.27e-05	0.000336	CcSEcCtD
Gefitinib—Malaise—Prednisone—prostate cancer	3.27e-05	0.000336	CcSEcCtD
Gefitinib—Shock—Capecitabine—prostate cancer	3.27e-05	0.000336	CcSEcCtD
Gefitinib—Body temperature increased—Etoposide—prostate cancer	3.27e-05	0.000335	CcSEcCtD
Gefitinib—Abdominal pain—Etoposide—prostate cancer	3.27e-05	0.000335	CcSEcCtD
Gefitinib—Conjunctivitis—Doxorubicin—prostate cancer	3.27e-05	0.000335	CcSEcCtD
Gefitinib—Nervous system disorder—Capecitabine—prostate cancer	3.26e-05	0.000335	CcSEcCtD
Gefitinib—Hepatitis—Epirubicin—prostate cancer	3.26e-05	0.000335	CcSEcCtD
Gefitinib—Haemorrhage—Epirubicin—prostate cancer	3.26e-05	0.000335	CcSEcCtD
Gefitinib—Thrombocytopenia—Capecitabine—prostate cancer	3.26e-05	0.000334	CcSEcCtD
Gefitinib—Skin disorder—Capecitabine—prostate cancer	3.23e-05	0.000331	CcSEcCtD
Gefitinib—Urinary tract disorder—Epirubicin—prostate cancer	3.22e-05	0.00033	CcSEcCtD
Gefitinib—Oedema peripheral—Epirubicin—prostate cancer	3.21e-05	0.00033	CcSEcCtD
Gefitinib—Hypotension—Docetaxel—prostate cancer	3.21e-05	0.000329	CcSEcCtD
Gefitinib—Haematuria—Doxorubicin—prostate cancer	3.2e-05	0.000329	CcSEcCtD
Gefitinib—Urethral disorder—Epirubicin—prostate cancer	3.2e-05	0.000328	CcSEcCtD
Gefitinib—Hepatobiliary disease—Doxorubicin—prostate cancer	3.18e-05	0.000326	CcSEcCtD
Gefitinib—Epistaxis—Doxorubicin—prostate cancer	3.17e-05	0.000325	CcSEcCtD
Gefitinib—Anorexia—Capecitabine—prostate cancer	3.17e-05	0.000325	CcSEcCtD
Gefitinib—Nausea—Estradiol—prostate cancer	3.17e-05	0.000325	CcSEcCtD
Gefitinib—Vomiting—Mitoxantrone—prostate cancer	3.16e-05	0.000324	CcSEcCtD
Gefitinib—Rash—Mitoxantrone—prostate cancer	3.13e-05	0.000322	CcSEcCtD
Gefitinib—Dermatitis—Mitoxantrone—prostate cancer	3.13e-05	0.000321	CcSEcCtD
Gefitinib—Hypotension—Capecitabine—prostate cancer	3.11e-05	0.000319	CcSEcCtD
Gefitinib—Erythema multiforme—Epirubicin—prostate cancer	3.08e-05	0.000316	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	3.07e-05	0.000315	CcSEcCtD
Gefitinib—Dyspnoea—Docetaxel—prostate cancer	3.06e-05	0.000314	CcSEcCtD
Gefitinib—Eye disorder—Epirubicin—prostate cancer	3.05e-05	0.000313	CcSEcCtD
Gefitinib—Hypersensitivity—Etoposide—prostate cancer	3.04e-05	0.000312	CcSEcCtD
Gefitinib—Haemoglobin—Doxorubicin—prostate cancer	3.03e-05	0.000311	CcSEcCtD
Gefitinib—Cardiac disorder—Epirubicin—prostate cancer	3.03e-05	0.000311	CcSEcCtD
Gefitinib—Hepatitis—Doxorubicin—prostate cancer	3.02e-05	0.00031	CcSEcCtD
Gefitinib—Haemorrhage—Doxorubicin—prostate cancer	3.02e-05	0.00031	CcSEcCtD
Gefitinib—Decreased appetite—Docetaxel—prostate cancer	2.98e-05	0.000306	CcSEcCtD
Gefitinib—Urinary tract disorder—Doxorubicin—prostate cancer	2.98e-05	0.000306	CcSEcCtD
Gefitinib—Oedema peripheral—Doxorubicin—prostate cancer	2.97e-05	0.000305	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Docetaxel—prostate cancer	2.96e-05	0.000304	CcSEcCtD
Gefitinib—Asthenia—Etoposide—prostate cancer	2.96e-05	0.000304	CcSEcCtD
Gefitinib—Dyspnoea—Capecitabine—prostate cancer	2.96e-05	0.000304	CcSEcCtD
Gefitinib—Fatigue—Docetaxel—prostate cancer	2.96e-05	0.000304	CcSEcCtD
Gefitinib—Angiopathy—Epirubicin—prostate cancer	2.96e-05	0.000304	CcSEcCtD
Gefitinib—Urethral disorder—Doxorubicin—prostate cancer	2.96e-05	0.000304	CcSEcCtD
Gefitinib—Nausea—Mitoxantrone—prostate cancer	2.95e-05	0.000303	CcSEcCtD
Gefitinib—Infection—Prednisone—prostate cancer	2.94e-05	0.000302	CcSEcCtD
Gefitinib—Mediastinal disorder—Epirubicin—prostate cancer	2.94e-05	0.000302	CcSEcCtD
Gefitinib—Pain—Docetaxel—prostate cancer	2.94e-05	0.000301	CcSEcCtD
Gefitinib—Constipation—Docetaxel—prostate cancer	2.94e-05	0.000301	CcSEcCtD
Gefitinib—Pruritus—Etoposide—prostate cancer	2.92e-05	0.0003	CcSEcCtD
Gefitinib—CHEK2—Levonorgestrel—Ethinyl Estradiol—prostate cancer	2.92e-05	0.0118	CbGdCrCtD
Gefitinib—Shock—Prednisone—prostate cancer	2.91e-05	0.000299	CcSEcCtD
Gefitinib—Arrhythmia—Epirubicin—prostate cancer	2.91e-05	0.000299	CcSEcCtD
Gefitinib—Nervous system disorder—Prednisone—prostate cancer	2.9e-05	0.000298	CcSEcCtD
Gefitinib—Decreased appetite—Capecitabine—prostate cancer	2.89e-05	0.000297	CcSEcCtD
Gefitinib—Alopecia—Epirubicin—prostate cancer	2.88e-05	0.000296	CcSEcCtD
Gefitinib—Skin disorder—Prednisone—prostate cancer	2.88e-05	0.000295	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Capecitabine—prostate cancer	2.87e-05	0.000295	CcSEcCtD
Gefitinib—Fatigue—Capecitabine—prostate cancer	2.87e-05	0.000294	CcSEcCtD
Gefitinib—Erythema multiforme—Doxorubicin—prostate cancer	2.85e-05	0.000293	CcSEcCtD
Gefitinib—Pain—Capecitabine—prostate cancer	2.84e-05	0.000292	CcSEcCtD
Gefitinib—Constipation—Capecitabine—prostate cancer	2.84e-05	0.000292	CcSEcCtD
Gefitinib—Malnutrition—Epirubicin—prostate cancer	2.84e-05	0.000291	CcSEcCtD
Gefitinib—Diarrhoea—Etoposide—prostate cancer	2.83e-05	0.00029	CcSEcCtD
Gefitinib—Anorexia—Prednisone—prostate cancer	2.82e-05	0.00029	CcSEcCtD
Gefitinib—Eye disorder—Doxorubicin—prostate cancer	2.82e-05	0.000289	CcSEcCtD
Gefitinib—Gastrointestinal pain—Docetaxel—prostate cancer	2.81e-05	0.000288	CcSEcCtD
Gefitinib—Erlotinib—CYP3A4—prostate cancer	2.8e-05	0.00652	CrCbGaD
Gefitinib—Cardiac disorder—Doxorubicin—prostate cancer	2.8e-05	0.000287	CcSEcCtD
Gefitinib—CSNK1E—Danazol—Prednisone—prostate cancer	2.79e-05	0.0113	CbGdCrCtD
Gefitinib—Angiopathy—Doxorubicin—prostate cancer	2.74e-05	0.000281	CcSEcCtD
Gefitinib—Gastrointestinal pain—Capecitabine—prostate cancer	2.72e-05	0.000279	CcSEcCtD
Gefitinib—Mediastinal disorder—Doxorubicin—prostate cancer	2.72e-05	0.000279	CcSEcCtD
Gefitinib—Body temperature increased—Docetaxel—prostate cancer	2.71e-05	0.000279	CcSEcCtD
Gefitinib—Abdominal pain—Docetaxel—prostate cancer	2.71e-05	0.000279	CcSEcCtD
Gefitinib—Arrhythmia—Doxorubicin—prostate cancer	2.69e-05	0.000277	CcSEcCtD
Gefitinib—Alopecia—Doxorubicin—prostate cancer	2.67e-05	0.000274	CcSEcCtD
Gefitinib—Urticaria—Capecitabine—prostate cancer	2.64e-05	0.000271	CcSEcCtD
Gefitinib—Cisapride—CYP3A4—prostate cancer	2.64e-05	0.00614	CrCbGaD
Gefitinib—Abdominal pain—Capecitabine—prostate cancer	2.63e-05	0.00027	CcSEcCtD
Gefitinib—Body temperature increased—Capecitabine—prostate cancer	2.63e-05	0.00027	CcSEcCtD
Gefitinib—Vomiting—Etoposide—prostate cancer	2.63e-05	0.00027	CcSEcCtD
Gefitinib—Malnutrition—Doxorubicin—prostate cancer	2.63e-05	0.00027	CcSEcCtD
Gefitinib—Anaemia—Epirubicin—prostate cancer	2.62e-05	0.000269	CcSEcCtD
Gefitinib—Rash—Etoposide—prostate cancer	2.61e-05	0.000267	CcSEcCtD
Gefitinib—Dermatitis—Etoposide—prostate cancer	2.6e-05	0.000267	CcSEcCtD
Gefitinib—Decreased appetite—Prednisone—prostate cancer	2.57e-05	0.000264	CcSEcCtD
Gefitinib—Malaise—Epirubicin—prostate cancer	2.56e-05	0.000263	CcSEcCtD
Gefitinib—Fatigue—Prednisone—prostate cancer	2.55e-05	0.000262	CcSEcCtD
Gefitinib—Constipation—Prednisone—prostate cancer	2.53e-05	0.00026	CcSEcCtD
Gefitinib—Hypersensitivity—Docetaxel—prostate cancer	2.53e-05	0.00026	CcSEcCtD
Gefitinib—Cough—Epirubicin—prostate cancer	2.48e-05	0.000254	CcSEcCtD
Gefitinib—Asthenia—Docetaxel—prostate cancer	2.46e-05	0.000253	CcSEcCtD
Gefitinib—Nausea—Etoposide—prostate cancer	2.45e-05	0.000252	CcSEcCtD
Gefitinib—Hypersensitivity—Capecitabine—prostate cancer	2.45e-05	0.000251	CcSEcCtD
Gefitinib—Iloperidone—CYP3A4—prostate cancer	2.43e-05	0.00567	CrCbGaD
Gefitinib—Pruritus—Docetaxel—prostate cancer	2.43e-05	0.000249	CcSEcCtD
Gefitinib—Anaemia—Doxorubicin—prostate cancer	2.43e-05	0.000249	CcSEcCtD
Gefitinib—Gastrointestinal pain—Prednisone—prostate cancer	2.42e-05	0.000249	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	2.4e-05	0.000246	CcSEcCtD
Gefitinib—Asthenia—Capecitabine—prostate cancer	2.39e-05	0.000245	CcSEcCtD
Gefitinib—Malaise—Doxorubicin—prostate cancer	2.37e-05	0.000243	CcSEcCtD
Gefitinib—Dry mouth—Epirubicin—prostate cancer	2.36e-05	0.000243	CcSEcCtD
Gefitinib—Urticaria—Prednisone—prostate cancer	2.35e-05	0.000241	CcSEcCtD
Gefitinib—Pruritus—Capecitabine—prostate cancer	2.35e-05	0.000241	CcSEcCtD
Gefitinib—Diarrhoea—Docetaxel—prostate cancer	2.35e-05	0.000241	CcSEcCtD
Gefitinib—Abdominal pain—Prednisone—prostate cancer	2.34e-05	0.00024	CcSEcCtD
Gefitinib—Body temperature increased—Prednisone—prostate cancer	2.34e-05	0.00024	CcSEcCtD
Gefitinib—Infection—Epirubicin—prostate cancer	2.3e-05	0.000236	CcSEcCtD
Gefitinib—Cough—Doxorubicin—prostate cancer	2.29e-05	0.000235	CcSEcCtD
Gefitinib—Shock—Epirubicin—prostate cancer	2.28e-05	0.000234	CcSEcCtD
Gefitinib—Diarrhoea—Capecitabine—prostate cancer	2.27e-05	0.000233	CcSEcCtD
Gefitinib—Nervous system disorder—Epirubicin—prostate cancer	2.27e-05	0.000233	CcSEcCtD
Gefitinib—Thrombocytopenia—Epirubicin—prostate cancer	2.27e-05	0.000233	CcSEcCtD
Gefitinib—Skin disorder—Epirubicin—prostate cancer	2.25e-05	0.000231	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	2.22e-05	0.000228	CcSEcCtD
Gefitinib—Anorexia—Epirubicin—prostate cancer	2.21e-05	0.000227	CcSEcCtD
Gefitinib—Dry mouth—Doxorubicin—prostate cancer	2.19e-05	0.000224	CcSEcCtD
Gefitinib—Vomiting—Docetaxel—prostate cancer	2.18e-05	0.000224	CcSEcCtD
Gefitinib—Hypersensitivity—Prednisone—prostate cancer	2.18e-05	0.000224	CcSEcCtD
Gefitinib—Rash—Docetaxel—prostate cancer	2.17e-05	0.000222	CcSEcCtD
Gefitinib—Hypotension—Epirubicin—prostate cancer	2.16e-05	0.000222	CcSEcCtD
Gefitinib—Dermatitis—Docetaxel—prostate cancer	2.16e-05	0.000222	CcSEcCtD
Gefitinib—Infection—Doxorubicin—prostate cancer	2.13e-05	0.000219	CcSEcCtD
Gefitinib—Asthenia—Prednisone—prostate cancer	2.12e-05	0.000218	CcSEcCtD
Gefitinib—Vomiting—Capecitabine—prostate cancer	2.11e-05	0.000217	CcSEcCtD
Gefitinib—Shock—Doxorubicin—prostate cancer	2.11e-05	0.000216	CcSEcCtD
Gefitinib—Nervous system disorder—Doxorubicin—prostate cancer	2.1e-05	0.000216	CcSEcCtD
Gefitinib—Thrombocytopenia—Doxorubicin—prostate cancer	2.1e-05	0.000215	CcSEcCtD
Gefitinib—Rash—Capecitabine—prostate cancer	2.1e-05	0.000215	CcSEcCtD
Gefitinib—Pruritus—Prednisone—prostate cancer	2.1e-05	0.000215	CcSEcCtD
Gefitinib—Dermatitis—Capecitabine—prostate cancer	2.09e-05	0.000215	CcSEcCtD
Gefitinib—Skin disorder—Doxorubicin—prostate cancer	2.08e-05	0.000214	CcSEcCtD
Gefitinib—Dyspnoea—Epirubicin—prostate cancer	2.06e-05	0.000212	CcSEcCtD
Gefitinib—Anorexia—Doxorubicin—prostate cancer	2.04e-05	0.00021	CcSEcCtD
Gefitinib—Nausea—Docetaxel—prostate cancer	2.04e-05	0.000209	CcSEcCtD
Gefitinib—Diarrhoea—Prednisone—prostate cancer	2.03e-05	0.000208	CcSEcCtD
Gefitinib—Decreased appetite—Epirubicin—prostate cancer	2.01e-05	0.000207	CcSEcCtD
Gefitinib—Hypotension—Doxorubicin—prostate cancer	2e-05	0.000206	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Epirubicin—prostate cancer	2e-05	0.000205	CcSEcCtD
Gefitinib—Fatigue—Epirubicin—prostate cancer	2e-05	0.000205	CcSEcCtD
Gefitinib—Constipation—Epirubicin—prostate cancer	1.98e-05	0.000203	CcSEcCtD
Gefitinib—Pain—Epirubicin—prostate cancer	1.98e-05	0.000203	CcSEcCtD
Gefitinib—Nausea—Capecitabine—prostate cancer	1.97e-05	0.000203	CcSEcCtD
Gefitinib—Dyspnoea—Doxorubicin—prostate cancer	1.91e-05	0.000196	CcSEcCtD
Gefitinib—Gastrointestinal pain—Epirubicin—prostate cancer	1.89e-05	0.000194	CcSEcCtD
Gefitinib—Vomiting—Prednisone—prostate cancer	1.88e-05	0.000193	CcSEcCtD
Gefitinib—Rash—Prednisone—prostate cancer	1.87e-05	0.000192	CcSEcCtD
Gefitinib—Dermatitis—Prednisone—prostate cancer	1.87e-05	0.000191	CcSEcCtD
Gefitinib—Decreased appetite—Doxorubicin—prostate cancer	1.86e-05	0.000191	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Doxorubicin—prostate cancer	1.85e-05	0.00019	CcSEcCtD
Gefitinib—Fatigue—Doxorubicin—prostate cancer	1.85e-05	0.00019	CcSEcCtD
Gefitinib—Vandetanib—CYP3A4—prostate cancer	1.84e-05	0.0043	CrCbGaD
Gefitinib—Urticaria—Epirubicin—prostate cancer	1.84e-05	0.000189	CcSEcCtD
Gefitinib—Constipation—Doxorubicin—prostate cancer	1.83e-05	0.000188	CcSEcCtD
Gefitinib—Pain—Doxorubicin—prostate cancer	1.83e-05	0.000188	CcSEcCtD
Gefitinib—Abdominal pain—Epirubicin—prostate cancer	1.83e-05	0.000188	CcSEcCtD
Gefitinib—Body temperature increased—Epirubicin—prostate cancer	1.83e-05	0.000188	CcSEcCtD
Gefitinib—CSNK1E—Betamethasone—Prednisone—prostate cancer	1.78e-05	0.00718	CbGdCrCtD
Gefitinib—CSNK1E—Dexamethasone—Prednisone—prostate cancer	1.78e-05	0.00718	CbGdCrCtD
Gefitinib—Nausea—Prednisone—prostate cancer	1.76e-05	0.000181	CcSEcCtD
Gefitinib—Gastrointestinal pain—Doxorubicin—prostate cancer	1.75e-05	0.00018	CcSEcCtD
Gefitinib—Bosutinib—CYP3A4—prostate cancer	1.73e-05	0.00402	CrCbGaD
Gefitinib—Hypersensitivity—Epirubicin—prostate cancer	1.71e-05	0.000175	CcSEcCtD
Gefitinib—Urticaria—Doxorubicin—prostate cancer	1.7e-05	0.000175	CcSEcCtD
Gefitinib—Body temperature increased—Doxorubicin—prostate cancer	1.69e-05	0.000174	CcSEcCtD
Gefitinib—Abdominal pain—Doxorubicin—prostate cancer	1.69e-05	0.000174	CcSEcCtD
Gefitinib—Asthenia—Epirubicin—prostate cancer	1.66e-05	0.000171	CcSEcCtD
Gefitinib—Pruritus—Epirubicin—prostate cancer	1.64e-05	0.000168	CcSEcCtD
Gefitinib—Diarrhoea—Epirubicin—prostate cancer	1.58e-05	0.000163	CcSEcCtD
Gefitinib—Hypersensitivity—Doxorubicin—prostate cancer	1.58e-05	0.000162	CcSEcCtD
Gefitinib—Asthenia—Doxorubicin—prostate cancer	1.54e-05	0.000158	CcSEcCtD
Gefitinib—Pruritus—Doxorubicin—prostate cancer	1.52e-05	0.000156	CcSEcCtD
Gefitinib—Vomiting—Epirubicin—prostate cancer	1.47e-05	0.000151	CcSEcCtD
Gefitinib—Diarrhoea—Doxorubicin—prostate cancer	1.47e-05	0.000151	CcSEcCtD
Gefitinib—Rash—Epirubicin—prostate cancer	1.46e-05	0.00015	CcSEcCtD
Gefitinib—Dermatitis—Epirubicin—prostate cancer	1.46e-05	0.00015	CcSEcCtD
Gefitinib—CHEK2—Danazol—Prednisone—prostate cancer	1.43e-05	0.00576	CbGdCrCtD
Gefitinib—Nausea—Epirubicin—prostate cancer	1.38e-05	0.000141	CcSEcCtD
Gefitinib—Vomiting—Doxorubicin—prostate cancer	1.36e-05	0.00014	CcSEcCtD
Gefitinib—Rash—Doxorubicin—prostate cancer	1.35e-05	0.000139	CcSEcCtD
Gefitinib—Dermatitis—Doxorubicin—prostate cancer	1.35e-05	0.000139	CcSEcCtD
Gefitinib—Nausea—Doxorubicin—prostate cancer	1.27e-05	0.000131	CcSEcCtD
Gefitinib—ABCB1—Metabolism—COMT—prostate cancer	7.48e-07	7.76e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—STAT3—prostate cancer	7.46e-07	7.73e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MAP2K1—prostate cancer	7.45e-07	7.72e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GSTP1—prostate cancer	7.45e-07	7.72e-06	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—AKT1—prostate cancer	7.43e-07	7.7e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PPARA—prostate cancer	7.43e-07	7.7e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GNG5—prostate cancer	7.43e-07	7.7e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CYP1A1—prostate cancer	7.4e-07	7.67e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PIK3CD—prostate cancer	7.4e-07	7.67e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CAV1—prostate cancer	7.39e-07	7.66e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—prostate cancer	7.38e-07	7.65e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—SRC—prostate cancer	7.38e-07	7.65e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—ERCC2—prostate cancer	7.34e-07	7.61e-06	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—PIK3CA—prostate cancer	7.33e-07	7.6e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ITPR1—prostate cancer	7.33e-07	7.6e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—RXRA—prostate cancer	7.32e-07	7.59e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SERPINE1—prostate cancer	7.32e-07	7.59e-06	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—KRAS—prostate cancer	7.27e-07	7.54e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—RXRA—prostate cancer	7.26e-07	7.52e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—KRAS—prostate cancer	7.25e-07	7.51e-06	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PIK3CB—prostate cancer	7.2e-07	7.46e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NCOA3—prostate cancer	7.15e-07	7.42e-06	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PTGS2—prostate cancer	7.14e-07	7.4e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—STAT3—prostate cancer	7.12e-07	7.38e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—TYMS—prostate cancer	7.09e-07	7.35e-06	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TP53—prostate cancer	7.09e-07	7.35e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—FGF2—prostate cancer	7.09e-07	7.34e-06	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—PIK3CA—prostate cancer	7.06e-07	7.32e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	7.06e-07	7.32e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—COMT—prostate cancer	7.05e-07	7.31e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GSTP1—prostate cancer	7.02e-07	7.27e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GSTM1—prostate cancer	7.01e-07	7.27e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—COMT—prostate cancer	6.99e-07	7.25e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NOS3—prostate cancer	6.99e-07	7.24e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CAV1—prostate cancer	6.98e-07	7.24e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GSTP1—prostate cancer	6.96e-07	7.21e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MYC—prostate cancer	6.93e-07	7.18e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—TYMS—prostate cancer	6.92e-07	7.18e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TGFB1—prostate cancer	6.91e-07	7.16e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ITPR1—prostate cancer	6.91e-07	7.16e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—MTHFR—prostate cancer	6.9e-07	7.15e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—LPL—prostate cancer	6.88e-07	7.13e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ITPR1—prostate cancer	6.85e-07	7.1e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GSTM1—prostate cancer	6.84e-07	7.09e-06	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TP53—prostate cancer	6.83e-07	7.08e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—HPGDS—prostate cancer	6.82e-07	7.07e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—JAK2—prostate cancer	6.79e-07	7.04e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP2C19—prostate cancer	6.78e-07	7.03e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—EGFR—prostate cancer	6.78e-07	7.02e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PPARA—prostate cancer	6.77e-07	7.02e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CG—prostate cancer	6.73e-07	6.98e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	6.73e-07	6.98e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—LPL—prostate cancer	6.72e-07	6.96e-06	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—PIK3CA—prostate cancer	6.68e-07	6.93e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	6.67e-07	6.92e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—PIK3CA—prostate cancer	6.66e-07	6.9e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CYP1A1—prostate cancer	6.65e-07	6.89e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MDM2—prostate cancer	6.63e-07	6.87e-06	CbGpPWpGaD
Gefitinib—EGFR—Immune System—KRAS—prostate cancer	6.62e-07	6.86e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ACHE—prostate cancer	6.62e-07	6.86e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSTT1—prostate cancer	6.62e-07	6.86e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—MYC—prostate cancer	6.61e-07	6.86e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—TGFB1—prostate cancer	6.6e-07	6.84e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ERCC2—prostate cancer	6.59e-07	6.83e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP2A6—prostate cancer	6.54e-07	6.78e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—ERBB2—prostate cancer	6.54e-07	6.78e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—TYMS—prostate cancer	6.52e-07	6.76e-06	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IL6—prostate cancer	6.49e-07	6.73e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CYP1A1—prostate cancer	6.49e-07	6.72e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—TYMS—prostate cancer	6.47e-07	6.7e-06	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TP53—prostate cancer	6.46e-07	6.7e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PIK3CB—prostate cancer	6.45e-07	6.69e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GSTM1—prostate cancer	6.45e-07	6.68e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ERCC2—prostate cancer	6.43e-07	6.67e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—KRAS—prostate cancer	6.4e-07	6.63e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GSTM1—prostate cancer	6.39e-07	6.63e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—INS—prostate cancer	6.37e-07	6.61e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CAV1—prostate cancer	6.37e-07	6.6e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—AKR1C3—prostate cancer	6.36e-07	6.6e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CG—prostate cancer	6.36e-07	6.59e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PRKACB—prostate cancer	6.33e-07	6.56e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—LPL—prostate cancer	6.33e-07	6.56e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—LPL—prostate cancer	6.28e-07	6.5e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP17A1—prostate cancer	6.27e-07	6.49e-06	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IL6—prostate cancer	6.25e-07	6.48e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CREBBP—prostate cancer	6.24e-07	6.47e-06	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PTEN—prostate cancer	6.22e-07	6.45e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CXCL8—prostate cancer	6.2e-07	6.43e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—MTHFR—prostate cancer	6.2e-07	6.42e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CYP1A1—prostate cancer	6.11e-07	6.34e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—KRAS—prostate cancer	6.11e-07	6.34e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	6.08e-07	6.31e-06	CbGpPWpGaD
Gefitinib—EGFR—Immune System—PIK3CA—prostate cancer	6.08e-07	6.3e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PPARA—prostate cancer	6.08e-07	6.3e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ERCC2—prostate cancer	6.06e-07	6.28e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CYP1A1—prostate cancer	6.06e-07	6.28e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CDKN1B—prostate cancer	6.05e-07	6.27e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—MTHFR—prostate cancer	6.05e-07	6.27e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—INS—prostate cancer	6.02e-07	6.24e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ERCC2—prostate cancer	6.01e-07	6.23e-06	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—AKT1—prostate cancer	5.99e-07	6.2e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NCOA2—prostate cancer	5.97e-07	6.19e-06	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—EP300—prostate cancer	5.93e-07	6.15e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PPARA—prostate cancer	5.93e-07	6.15e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CASP3—prostate cancer	5.93e-07	6.15e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL2—prostate cancer	5.92e-07	6.14e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CD—prostate cancer	5.92e-07	6.14e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CREBBP—prostate cancer	5.9e-07	6.11e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—IL6—prostate cancer	5.89e-07	6.11e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—PIK3CA—prostate cancer	5.88e-07	6.1e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CG—prostate cancer	5.8e-07	6.01e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCND1—prostate cancer	5.77e-07	5.99e-06	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—AKT1—prostate cancer	5.77e-07	5.98e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CTNNB1—prostate cancer	5.72e-07	5.93e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CAV1—prostate cancer	5.72e-07	5.92e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—MTHFR—prostate cancer	5.7e-07	5.91e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—SLC5A5—prostate cancer	5.7e-07	5.9e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TP53—prostate cancer	5.69e-07	5.9e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—MTHFR—prostate cancer	5.65e-07	5.86e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—PIK3CA—prostate cancer	5.62e-07	5.82e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MMP9—prostate cancer	5.61e-07	5.81e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CD—prostate cancer	5.59e-07	5.8e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PPARA—prostate cancer	5.59e-07	5.8e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—NOS3—prostate cancer	5.59e-07	5.79e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CDKN1A—prostate cancer	5.59e-07	5.79e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CAV1—prostate cancer	5.58e-07	5.78e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PTEN—prostate cancer	5.57e-07	5.78e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP2E1—prostate cancer	5.56e-07	5.77e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PPARA—prostate cancer	5.54e-07	5.75e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NQO1—prostate cancer	5.5e-07	5.7e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—INS—prostate cancer	5.49e-07	5.69e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	5.46e-07	5.66e-06	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—AKT1—prostate cancer	5.46e-07	5.66e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—AKT1—prostate cancer	5.44e-07	5.64e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—TH—prostate cancer	5.42e-07	5.62e-06	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL6—prostate cancer	5.39e-07	5.58e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CREBBP—prostate cancer	5.38e-07	5.57e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—EP300—prostate cancer	5.32e-07	5.51e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—NOS3—prostate cancer	5.28e-07	5.47e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP1B1—prostate cancer	5.27e-07	5.47e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CAV1—prostate cancer	5.26e-07	5.45e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CAV1—prostate cancer	5.21e-07	5.4e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IL6—prostate cancer	5.21e-07	5.4e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CG—prostate cancer	5.21e-07	5.4e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SRC—prostate cancer	5.17e-07	5.36e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CB—prostate cancer	5.16e-07	5.35e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PTGS2—prostate cancer	5.11e-07	5.3e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GGT1—prostate cancer	5.11e-07	5.29e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CD—prostate cancer	5.1e-07	5.28e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CG—prostate cancer	5.08e-07	5.27e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—VEGFA—prostate cancer	5.03e-07	5.22e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NCOA1—prostate cancer	5.03e-07	5.22e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—STAT3—prostate cancer	4.99e-07	5.17e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	4.98e-07	5.16e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—IL6—prostate cancer	4.97e-07	5.15e-06	CbGpPWpGaD
Gefitinib—EGFR—Immune System—AKT1—prostate cancer	4.97e-07	5.15e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP19A1—prostate cancer	4.96e-07	5.14e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—INS—prostate cancer	4.93e-07	5.11e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CB—prostate cancer	4.88e-07	5.05e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTGS2—prostate cancer	4.83e-07	5.01e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CREBBP—prostate cancer	4.83e-07	5e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—NOS3—prostate cancer	4.81e-07	4.99e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—INS—prostate cancer	4.81e-07	4.99e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—AKT1—prostate cancer	4.8e-07	4.98e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CG—prostate cancer	4.79e-07	4.96e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—RXRA—prostate cancer	4.79e-07	4.96e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CG—prostate cancer	4.75e-07	4.92e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CREBBP—prostate cancer	4.71e-07	4.88e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MYC—prostate cancer	4.63e-07	4.8e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TGFB1—prostate cancer	4.62e-07	4.79e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—COMT—prostate cancer	4.61e-07	4.78e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSTP1—prostate cancer	4.59e-07	4.76e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—AKT1—prostate cancer	4.59e-07	4.75e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CD—prostate cancer	4.58e-07	4.74e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—INS—prostate cancer	4.53e-07	4.7e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ITPR1—prostate cancer	4.51e-07	4.68e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—INS—prostate cancer	4.49e-07	4.66e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CD—prostate cancer	4.47e-07	4.63e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PTEN—prostate cancer	4.46e-07	4.62e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CB—prostate cancer	4.44e-07	4.61e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CREBBP—prostate cancer	4.44e-07	4.6e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTGS2—prostate cancer	4.4e-07	4.56e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CREBBP—prostate cancer	4.4e-07	4.56e-06	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PIK3CA—prostate cancer	4.39e-07	4.55e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—NOS3—prostate cancer	4.32e-07	4.48e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—KRAS—prostate cancer	4.28e-07	4.44e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—TYMS—prostate cancer	4.27e-07	4.42e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—EP300—prostate cancer	4.25e-07	4.41e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—NOS3—prostate cancer	4.22e-07	4.37e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSTM1—prostate cancer	4.22e-07	4.37e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTEN—prostate cancer	4.21e-07	4.37e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CD—prostate cancer	4.21e-07	4.36e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CD—prostate cancer	4.17e-07	4.33e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—LPL—prostate cancer	4.14e-07	4.29e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—EP300—prostate cancer	4.02e-07	4.16e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP1A1—prostate cancer	4e-07	4.14e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CB—prostate cancer	3.99e-07	4.14e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—NOS3—prostate cancer	3.98e-07	4.12e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ERCC2—prostate cancer	3.96e-07	4.11e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTGS2—prostate cancer	3.95e-07	4.1e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—NOS3—prostate cancer	3.94e-07	4.08e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PIK3CA—prostate cancer	3.93e-07	4.08e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CB—prostate cancer	3.89e-07	4.04e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTGS2—prostate cancer	3.86e-07	4e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTEN—prostate cancer	3.84e-07	3.98e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TP53—prostate cancer	3.8e-07	3.94e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—MTHFR—prostate cancer	3.73e-07	3.86e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CB—prostate cancer	3.67e-07	3.8e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—EP300—prostate cancer	3.66e-07	3.8e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PPARA—prostate cancer	3.66e-07	3.79e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CB—prostate cancer	3.64e-07	3.77e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTGS2—prostate cancer	3.64e-07	3.77e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTGS2—prostate cancer	3.6e-07	3.74e-06	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—AKT1—prostate cancer	3.59e-07	3.72e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL6—prostate cancer	3.48e-07	3.61e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTEN—prostate cancer	3.45e-07	3.57e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CAV1—prostate cancer	3.44e-07	3.56e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTEN—prostate cancer	3.36e-07	3.49e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—EP300—prostate cancer	3.29e-07	3.41e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—AKT1—prostate cancer	3.21e-07	3.33e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—EP300—prostate cancer	3.21e-07	3.33e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTEN—prostate cancer	3.17e-07	3.29e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CA—prostate cancer	3.15e-07	3.26e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTEN—prostate cancer	3.14e-07	3.26e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CG—prostate cancer	3.13e-07	3.25e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—EP300—prostate cancer	3.02e-07	3.13e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—EP300—prostate cancer	3e-07	3.11e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CA—prostate cancer	2.97e-07	3.08e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—INS—prostate cancer	2.96e-07	3.07e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CREBBP—prostate cancer	2.9e-07	3.01e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CD—prostate cancer	2.75e-07	2.85e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CA—prostate cancer	2.71e-07	2.81e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NOS3—prostate cancer	2.6e-07	2.69e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—AKT1—prostate cancer	2.57e-07	2.66e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CA—prostate cancer	2.43e-07	2.52e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—AKT1—prostate cancer	2.43e-07	2.52e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CB—prostate cancer	2.4e-07	2.49e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTGS2—prostate cancer	2.38e-07	2.46e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CA—prostate cancer	2.37e-07	2.46e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CA—prostate cancer	2.24e-07	2.32e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CA—prostate cancer	2.22e-07	2.3e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—AKT1—prostate cancer	2.21e-07	2.29e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTEN—prostate cancer	2.07e-07	2.15e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—AKT1—prostate cancer	1.99e-07	2.06e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—EP300—prostate cancer	1.98e-07	2.05e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—AKT1—prostate cancer	1.94e-07	2.01e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—AKT1—prostate cancer	1.83e-07	1.89e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—AKT1—prostate cancer	1.81e-07	1.88e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.46e-07	1.52e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—AKT1—prostate cancer	1.19e-07	1.24e-06	CbGpPWpGaD
